Recent FDA activity involving biosimilars to Prolia® and Xolair® highlights the continued expansion of biosimilar development across specialty care.
In March 2026, the U.S. Food and Drug Administration (FDA) approved PONLIMSI™ (denosumab-adet), a biosimilar to Prolia® (denosumab), and accepted a Biologics License Application (BLA) for review of a proposed biosimilar to Xolair® (omalizumab). Together, these developments highlight the steady advancement of biosimilars into additional areas of specialty medicine.
For specialty practices, ongoing biosimilar activity may influence future treatment access, formulary decisions, payer dynamics, and operational planning across multiple therapeutic categories.
Key Takeaways
- FDA approved PONLIMSI™, a biosimilar to Prolia® (denosumab)
- FDA accepted a BLA for review of a proposed Xolair® (omalizumab) biosimilar
- Biosimilar development continues to expand across specialty therapeutic areas
- Specialty practices may benefit from monitoring emerging approvals, formulary changes, and payer policies as the market evolves
FDA Approves Prolia® Biosimilar PONLIMSI™
PONLIMSI™, developed by Teva, received FDA approval as a biosimilar to Prolia® following a review of analytical and clinical data demonstrating that it is comparable in efficacy, safety, and immunogenicity to the reference product.
The biosimilar is approved for all indications held by Prolia®, including the treatment of osteoporosis in certain high-risk patient populations and bone loss associated with specific cancer therapies.
The approval adds to the growing number of biosimilars becoming available across specialty care, including treatment areas that historically had fewer alternatives.
Proposed Xolair® Biosimilar Advances to Regulatory Review
In a separate milestone, the FDA accepted a BLA for review of Teva’s proposed biosimilar to Xolair® (omalizumab), a biologic therapy commonly used to treat conditions including allergic asthma, chronic spontaneous urticaria, and chronic rhinosinusitis with nasal polyps. The application is supported by analytical and clinical data intended to demonstrate biosimilarity to the reference product.
While acceptance of a BLA does not guarantee approval, it marks an important step in the regulatory process and signals that additional biosimilar options may continue to emerge within allergy, asthma, and immunology treatment areas.
What These Developments Mean for Specialty Practices
For specialty practices, each new biosimilar approval or regulatory filing represents more than a product announcement. It reflects the ongoing evolution of a market that is increasingly influencing treatment access, reimbursement discussions, contracting strategies, and patient care planning.
As more biosimilars enter rheumatology, gastroenterology, oncology, immunology, and other specialty fields, practices may encounter a growing number of therapeutic alternatives to established reference biologics.
These changes can create opportunities to improve patient access while also requiring providers to stay current on product availability, payer policies, formulary changes, and reimbursement considerations.
Importantly, biosimilar development is now extending beyond well-established categories such as anti-TNF therapies into additional specialty treatment areas, including osteoporosis and allergy-related conditions.
Staying Informed as the Market Evolves
The pace of biosimilar development shows little sign of slowing. FDA approvals, regulatory reviews, and expanding manufacturer pipelines suggest that specialty providers will likely continue to see new biosimilar entrants across a broad range of therapeutic categories in the coming years.
For practices operating in a rapidly changing reimbursement and treatment environment, maintaining awareness of biosimilar developments can support proactive planning and informed decision-making.
Monitoring emerging products, payer trends, and regulatory milestones can help providers prepare for future changes while continuing to deliver high-quality patient care.
As the specialty biosimilar market matures, developments such as the approval of PONLIMSI™ and the review of a proposed Xolair® biosimilar further indicate that biosimilars will remain an increasingly important part of the specialty care landscape.
